Potential u.s. tariffs on pharmaceuticals expected to have minimal impact on alvotech's product revenues in 2025

Alvotech (nasdaq: alvo) (the “company”) a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today issued a statement on the anticipated impact of potential tariffs on imported pharmaceuticals to the united states. alvotech expects that potential u.s. tariffs on imported pharmaceuticals should have minimal impact on the company's product revenues in 2025. alvotech manufactures its biosimilars in iceland, a country which currently faces the minimum tariff of 10% on goods imported to the u.s. a 10% tariff on pharmaceuticals would raise the cost of biosimilars from alvotech imported to the u.s. for customers by less than 1% of alvotech's expected total product revenues in 2025. furthermore, according to contracted terms, customers are responsible for all costs of transport and import duties to the u.s., and these costs are therefore not expected to be paid by alvotech.
ALVO Ratings Summary
ALVO Quant Ranking